{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:17:45Z","timestamp":1788513465587,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","funder":[{"DOI":"10.13039\/100022752","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir\/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48\u2005weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve participants completed 48\u2005weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA\u200a&amp;lt;\u200a50\u2005copies\/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1\u20133). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11\/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir\/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure\u2014particularly in combination with darunavir\/cobicistat\u2014 support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag297","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:42:44Z","timestamp":1787658164000},"source":"Crossref","is-referenced-by-count":0,"title":["Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study"],"prefix":"10.1093","volume":"81","author":[{"given":"Abiu","family":"Sempere","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-5206","authenticated-orcid":false,"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-3457","authenticated-orcid":false,"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-829X","authenticated-orcid":false,"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0894-3711","authenticated-orcid":false,"given":"Ana","family":"Gonzalez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Mar","family":"Mosquera Cepeda","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-6545","authenticated-orcid":false,"given":"Elisa","family":"De Lazzari","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2301-4101","authenticated-orcid":false,"given":"Mar\u00eda","family":"Martinez Rebollar","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4726","authenticated-orcid":false,"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Chivite","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Callau","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-3766","authenticated-orcid":false,"given":"Julia","family":"Calvo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-141X","authenticated-orcid":false,"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-3186","authenticated-orcid":false,"given":"Alberto","family":"Foncillas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Miro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Rigo-Bonnin","sequence":"additional","affiliation":[{"name":"Laboratori Cl\u00ednic, Hospital de Bellvitge , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednic-IDIBAPS & University of Barcelona, Hospital Cl\u00ednic de Barcelona , Barcelona 08036 ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona, Barcelona ,","place":["Spain"]},{"name":"Institut d\u2019Investigacions M\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2026090405061129700_dkag297-B1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2019-11-4","article-title":"Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection","volume":"9","author":"Pham","year":"2020","journal-title":"Drugs Context"},{"key":"2026090405061129700_dkag297-B2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3851\/IMP3323","article-title":"Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a phase IIb trial","volume":"24","author":"Gatell","year":"2019","journal-title":"Antivir Ther"},{"key":"2026090405061129700_dkag297-B3","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"2026090405061129700_dkag297-B4","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090405061129700_dkag297-B5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090405061129700_dkag297-B6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090405061129700_dkag297-B7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/QAI.0000000000001031","article-title":"Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants","volume":"72","author":"Smith","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026090405061129700_dkag297-B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/cbdd.13766","article-title":"Structure-based non-nucleoside inhibitor design: developing inhibitors that are effective against resistant mutants","volume":"97","author":"Smith","year":"2021","journal-title":"Chem Biol Drug Des"},{"key":"2026090405061129700_dkag297-B9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/COH.0000000000000471","article-title":"Doravirine: a review","volume":"13","author":"Colombier","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"2026090405061129700_dkag297-B10","author":"European AIDS Clinical Society"},{"key":"2026090405061129700_dkag297-B11"},{"key":"2026090405061129700_dkag297-B12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate maintains HIV-1 virologic suppression through 48\u2005weeks: results of the DRIVE-SHIFT trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026090405061129700_dkag297-B13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/QAD.0000000000004151","article-title":"Use of doravirine-based regimens in clinical practice in Europe","volume":"39","author":"Rami","year":"2025","journal-title":"AIDS"},{"key":"2026090405061129700_dkag297-B14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/jac\/dkz553","article-title":"Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy","volume":"75","author":"Souli\u00e9","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026090405061129700_dkag297-B15","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/QAI.0000000000002153","article-title":"Efficacy and safety of doravirine\/lamivudine\/tenofovir disoproxil fumarate in treatment-naive adults with HIV-1 and transmitted nonnucleoside reverse transcriptase inhibitor resistance mutations","volume":"82","author":"Wong","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026090405061129700_dkag297-B16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/QAI.0000000000003248","article-title":"Doravirine plus integrase strand transfer inhibitors as a 2-drug treatment-switch strategy in people living with HIV: the real-life DORINI multicentric cohort study","volume":"94","author":"Poliseno","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026090405061129700_dkag297-B17","author":"Brumme"},{"key":"2026090405061129700_dkag297-B18","doi-asserted-by":"publisher","first-page":"117678","DOI":"10.1016\/j.cca.2023.117678","article-title":"Development and validation of equilibrium dialysis UHPLC\u2013MS\/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma: application to patients with HIV","volume":"552","author":"Rigo-Bonnin","year":"2024","journal-title":"Clin Chim Acta"},{"key":"2026090405061129700_dkag297-B19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/hiv.70061","article-title":"Resistance profile of darunavir: combined analysis of clinical data","volume":"13","author":"De Meyer","year":"2008","journal-title":"Antivir Ther"},{"key":"2026090405061129700_dkag297-B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jmv.23404","article-title":"Switching to darunavir\/ritonavir 800\/100\u2005mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1","volume":"85","author":"Ghosn","year":"2013","journal-title":"J Med Virol"},{"key":"2026090405061129700_dkag297-B21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/jac\/dkx459","article-title":"Pharmacokinetics of darunavir\/cobicistat and etravirine alone and co-administered in HIV-infected patients","volume":"73","author":"Molt\u00f3","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026090405061129700_dkag297-B22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3851\/IMP2812","article-title":"Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir","volume":"20","author":"Blanco","year":"2015","journal-title":"Antivir Ther"},{"key":"2026090405061129700_dkag297-B23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/hiv.70061","article-title":"Effectiveness of switching to doravirine-based antiretroviral therapy: a real-world study in Germany","volume":"26","author":"Wyen","year":"2025","journal-title":"HIV Med"},{"key":"2026090405061129700_dkag297-B24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf356","article-title":"Efficacy and safety of doravirine-based regimens by sex and race: long-term results from three phase 3 clinical trials","volume":"12","author":"Walmsley","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026090405061129700_dkag297-B25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12981-025-00761-5","article-title":"Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study","volume":"22","author":"Mounzer","year":"2025","journal-title":"AIDS Res Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag297\/70952212\/dkag297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag297\/70952212\/dkag297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:06:19Z","timestamp":1788512779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag297\/8785334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag297","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"dkag297"}}